AlphaStocks

BIO vs MEDP

As of Sep 20, 2026, Bio-Rad Laboratories (BIO) scores 7.4/10 and Medpace Holdings (MEDP) 6.0/10 on AlphaStocks' five-model composite, so BIO scores higher. MEDP trades 49% above its model fair value.

BIO

BIO-RAD LABORATORIES, INC.

7.4

Consider Buy

$375.68

MEDP

Medpace Holdings, Inc.

6.0

Consider Buy

$612.42

BIO vs MEDP: Which is the Better Investment?

BIO-RAD LABORATORIES, INC. (BIO) scores 7.4/10 while Medpace Holdings, Inc. (MEDP) scores 6.0/10 on AlphaStocks' composite model. BIO-RAD LABORATORIES, INC. has the higher composite rating of Consider Buy. On a P/E basis, BIO-RAD LABORATORIES, INC. trades at 13.5x, making it the more attractively priced of the two.

This comparison is algorithmically generated and is not financial advice.

MetricBIOMEDP
Scores & Fundamentals
Composite Score7.4/106.0/10
RatingConsider BuyConsider Buy
Price$375.68$612.42
P/E Ratio13.540.1
ROE9.7%48.9%
Market Cap$10B$18B
Fair Value$410.35
Dividend Yield
Sector Rank#7 of 168#51 of 168
Model Verdicts
PiotroskiAttractiveAttractive
BuffettNeutralNeutral
GrahamAttractiveCaution
LynchAttractiveStrong
GreenblattStrongLimited Data
View full BIOanalysis →View full MEDPanalysis →

Related comparisons

Compare any two stocks →

BIO vs MEDP: Which Stock Scores Higher?

BIO-RAD LABORATORIES, INC. (BIO) and Medpace Holdings, Inc. (MEDP) are both in the Health Care sector. BIO currently leads with a composite score of 7.4/10 (Consider Buy) compared to MEDP's 6.0/10 (Consider Buy).

The AlphaStocks composite score evaluates each stock across four dimensions: Quality (business strength measured by Piotroski F-Score and Buffett quality criteria), Value (discount to intrinsic worth using Graham, Lynch, and Greenblatt models), Momentum (6-month price trend), and Timing (a confirmation signal that requires both value and momentum to align). A higher composite score indicates stronger overall fundamentals combined with favorable market conditions.

This comparison uses the same scoring framework for both companies, ensuring an apples-to-apples evaluation. Scores are recalculated daily after market close using data from SEC filings and market prices. Read the full methodology to understand how each model contributes to the composite score.

Scores are algorithm-generated research tools, not investment recommendations. Past performance does not guarantee future results. Always do your own due diligence. Full disclaimer